Fate Therapeutics

Company Overview

Fate Therapeutics is a biotechnology company that develops novel stem cell modulators, biologic or small-molecule compounds that guide cell fate, to treat patients with very few therapeutic options. ProHema, Fate Therapeutics’ lead clinical program, consists of pharmacologically enhanced hematopoietic stem cells (HSCs) designed to improve HSC support during the regular course of a stem cell transplant for the treatment of patients with hematologic malignancies.

Fate Therapeutics is also developing a robust pipeline of human recombinant proteins, each with novel mechanisms of action, for skeletal muscle, beta-islet cell, and post-ischemic tissue regeneration. Fate Therapeutics applies its proprietary iPSC technology to offer a platform to recapitulate human physiology for commercial-scale drug discovery and therapeutic use. Fate Therapeutics is headquartered in San Diego and has a subsidiary in Ottawa, Canada.

Financial Highlights (FY 2024)

Company's Business Segments

• Products : The company generates revenue through two product lines, CAR T-CELL, and CAR NK CELL, for Oncology and Autoimmunity.
• Collaborations : The company generates revenue through collaboration with other medical centers such as ONO Pharmaceuticals Co Ltd., Masonic Cancer Center at the University of Minnesota, Memorial Sloan- Kettering Cancer Center, and Oslo University Hospital.